RNS Number : 8534S
GoldmanSachs International
12 February 2026
FORM 38.5(b)
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITHOUT RECOGNISED INTERMEDIARY STATUS, OR WITH RECOGNISED INTERMEDIARY STATUS BUT NOT DEALING IN A CLIENT-SERVING CAPACITY
1. KEY INFORMATION
Name of exempt principal trader
(GS) GOLDMAN SACHS INTERNATIONAL
Company dealt in
AVADEL PHARMACEUTICALS PLC
Class of relevant security to which the dealings being disclosed relate (Note1)
USD 0.01 ordinary shares
Date of dealing
11 February 2026
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 2)
Long
Short
Number
(%)
Number
(%)
(1) Relevant securities
3,136
(0.00)
0
(0.00)
(2) Derivatives (other than options)
0
(0.00)
0
(0.00)
(3) Options and agreements to purchase/sell
0
(0.00)
0
(0.00)
Total
3,136
(0.00)
0
(0.00)
(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 2)
Class of relevant security:
Long
Short
Number
(%)
Number
(%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total
3. DEALINGS (Note 3)
(a) Purchases and sales
Purchase/sale
Number of relevant securities
Price per unit (Note 4)
Sale (Borrow Full Return)
356
N/A
(b) Derivatives transactions (other than options transactions)
Product name, e.g. CFD
Nature of transaction (Note 5)
Number of relevant securities (Note 6)
Price per unit (Note 4)
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product name,e.g. call option
Writing, selling, purchasing, varying etc.
Number of securities to which the option relates (Note 7)
Exercise price
Type, e.g. American, European etc.
Expiry date
Option money paid/received per unit (Note 4)
(ii) Exercising
Product name,e.g. call option
Number of securities
Exercise price per unit (Note 4)
(d) Other dealings (including transactions in respect of new securities) (Note 3)
Nature of transaction (Note 7)
Details
Price per unit (if applicable) (Note 4)
4. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.
NONE
Is a Supplemental Form 8 attached? (Note 9) NO
Date of disclosure
12 February 2026
Contact name
Papa Lette and Andrzej Szyszka
Telephone number
+33(1) 4212 1459 / +48(22) 317 4817
Name of offeree/offeror with which connected
AVADEL PHARMACEUTICALS PLC
Nature of connection (Note 9)
Advisor to Offeree
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
ITPGPUGUPUPQPUP
